Asandeutertinib - TYK Medicine
Alternative Names: TY-9591; TYK 9591Latest Information Update: 26 Aug 2025
At a glance
- Originator TYK Medicine
- Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Indoles; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- No development reported Brain metastases; Solid tumours
Most Recent Events
- 26 Aug 2025 Chemical structure information added.
- 30 May 2025 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)